Status: Recruiting
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
The purpose of this study is as follows: 1. Determine whether people receiving the combination treatment of olutasidenib, venetoclax, and azacitidine have the same, more, or fewer side effects compared to the usual chemotherapy treatment that people with this condition receive. 2. Determine how well the combination treatment of olutasidenib, venetoclax, and azacitidine works compared to the usual chemotherapy treatment that people with this condition receive.
Participants needed: 16
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Justin Watts, MDUpdated: Apr 16, 2026Locations: 1
Eligibility criteria
Participant is an adult male or female participant aged 18-75 years considered e... [+18]
Relapsed/Refractory AML. [+17]